| 日付 |
時間 |
ソース |
タイトル |
|---|
| 2024/4/29 | 20:57 | GLOBE | ZyVersa Therapeutics Announces Publication Reinforcing the.. |
| 2024/4/04 | 20:57 | GLOBE | ZyVersa Therapeutics Highlights Published Data Demonstrating.. |
| 2024/3/25 | 21:17 | GLOBE | ZyVersa Therapeutics Reports Full Year 2023 Financial.. |
| 2024/3/18 | 20:57 | GLOBE | ZyVersa Therapeutics Announces IRB Approval of Phase 2a.. |
| 2024/3/14 | 20:57 | GLOBE | ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate.. |
| 2024/3/09 | 07:00 | EDGAR2 | Form 8-K - Current report |
| 2024/3/09 | 07:00 | EDGAR2 | Form PRE 14A - Other preliminary proxy statements |
| 2024/2/29 | 21:57 | GLOBE | ZyVersa Therapeutics Generated Approximately $2.7 Million.. |
| 2024/2/28 | 21:57 | GLOBE | ZyVersa Therapeutics Highlights Data from Review Article.. |
| 2024/2/22 | 21:47 | GLOBE | ZyVersa Therapeutics Publishes New White Paper Detailing the.. |
| 2024/2/15 | 06:34 | EDGAR2 | Form S-8 - Securities to be offered to employees in employee.. |
| 2024/2/14 | 21:53 | GLOBE | ZyVersa Therapeutics Highlights Review Article.. |
| 2024/2/07 | 22:02 | GLOBE | ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at.. |
| 2024/1/31 | 21:57 | GLOBE | ZyVersa Therapeutics Highlights Publication Indicating That.. |
| 2024/1/24 | 21:57 | GLOBE | ZyVersa Therapeutics Announces Peer-Reviewed Article.. |
| 2024/1/19 | 20:19 | EDGAR2 | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2024/1/17 | 21:52 | GLOBE | ZyVersa Therapeutics Highlights Peer-Reviewed Article.. |
| 2024/1/10 | 22:06 | GLOBE | ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on.. |
| 2024/1/04 | 21:50 | GLOBE | ZyVersa Therapeutics Announces Equity Research Coverage.. |
| 2024/1/03 | 22:07 | GLOBE | ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter.. |
| 2023/12/23 | 06:45 | EDGAR2 | Form 8-K - Current report |
| 2023/12/18 | 22:12 | GLOBE | ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate.. |
| 2023/12/14 | 21:01 | GLOBE | ZyVersa Therapeutics Engages CRO, George Clinical, for Phase.. |
| 2023/12/12 | 06:30 | EDGAR2 | Form 8-K - Current report |
| 2023/12/09 | 06:44 | EDGAR2 | Form 424B4 - Prospectus [Rule 424(b)(4)] |
| 2023/12/08 | 01:20 | GLOBE | ZyVersa Therapeutics Announces Publication Demonstrating.. |
| 2023/12/07 | 14:15 | EDGAR2 | Form EFFECT - Notice of Effectiveness |
| 2023/12/07 | 11:00 | GLOBE | ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million.. |
| 2023/12/06 | 21:20 | GLOBE | ZyVersa Therapeutics Announces Publication Showing AIM2 and.. |
| 2023/12/01 | 01:45 | EDGAR2 | Form 8-K - Current report |
| 2023/12/01 | 01:30 | GLOBE | ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and.. |
| 2023/11/21 | 07:15 | EDGAR2 | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 2023/11/18 | 06:15 | EDGAR2 | Form 8-K - Current report |
| 2023/11/15 | 06:35 | GLOBE | ZyVersa Therapeutics Reports Third Quarter 2023 Corporate.. |
| 2023/11/09 | 21:35 | GLOBE | ZyVersa Therapeutics Announces Article Published in.. |
| 2023/11/06 | 21:05 | GLOBE | ZyVersa Therapeutics Announces Article in Peer-Reviewed.. |
| 2023/11/03 | 05:37 | EDGAR2 | Form 8-K - Current report |
| 2023/11/01 | 21:07 | GLOBE | ZyVersa Therapeutics Announces Publication in Molecular.. |
| 2023/10/25 | 19:50 | GLOBE | ZyVersa Therapeutics Announces Research Published in the.. |
| 2023/10/25 | 05:15 | EDGAR2 | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 2023/10/18 | 20:05 | GLOBE | ZyVersa Therapeutics Announces a Publication in the.. |
| 2023/10/18 | 05:15 | EDGAR2 | Form S-1/A - General form for registration of securities.. |
| 2023/10/11 | 20:05 | GLOBE | ZyVersa Therapeutics Announces Peer-Reviewed Publication in.. |
| 2023/10/04 | 20:05 | GLOBE | ZyVersa Therapeutics Announces New Peer-Reviewed Publication.. |
| 2023/9/27 | 20:07 | GLOBE | ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate.. |
| 2023/9/22 | 19:35 | GLOBE | ZyVersa Therapeutics Announces Research Published in The.. |
| 2023/9/21 | 06:15 | EDGAR2 | Form 8-K/A - Current report: [Amend] |
| 2023/9/14 | 20:00 | EDGAR2 | Form 8-K - Current report |
| 2023/9/14 | 05:57 | EDGAR2 | Form DEFA14A - Additional definitive proxy soliciting.. |
| 2023/9/14 | 05:40 | EDGAR2 | Form DEF 14A - Other definitive proxy statements |
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
